Broadening of generalized anxiety disorders definition does not affect the response to psychiatric care: Findings from the observational ADAN study

Clinical Practice and Epidemiology in Mental Health

Volumn 8, Issue , 2012, Pages 158-168

  Álvarez, Enrique ^a   Carrasco, Jose L ^b   Olivares, José M ^c   López Gómez, Vanessa ^d   Vilardaga, Inma ^e   Perez, María ^d  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL DO MEIXOEIRO   (Spain)

^d PFIZER INC   (United States)

^e European Biometrics Institute   (Spain)

Author keywords

Diagnostic and Statistical Manual of Mental Disorders; Generalized anxiety disorder; Hamilton Anxiety Rating Scale; Self reported quality of life

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE;

ADULT; ARTICLE; DSM-IV; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PSYCHOPHARMACOLOGY; TREATMENT RESPONSE;

EID: 84878149158     PISSN: None     EISSN: 17450179     Source Type: Journal    
DOI: 10.2174/1745017901208010158     Document Type: Article

References (34)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV TR, Washington DC, 2000.
2. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 420: 21-7.
3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602. (Pubitemid 40973434)
4. Stein DJ. Comorbidity in generalized anxiety disorder: impact and implications. J Clin Psychiatry 2001; 62 (Suppl 11): 29-34; discussion 35-26.
5. Caballero L, Bobes J, Vilardaga I, Rejas J. [Clinical prevalence and reason for visit of patients with generalized anxiety disorder seen in the psychiatry out-patient clinics in Spain. Results of the LIGANDO study]. Actas Esp Psiquiatr 2009; 37: 17-20.
6. Chocron BL, Vilalta FJ, Legazpi RI, Auquer K, Franch L. Prevalence of psychopathology at a primary care center. Aten Primaria 1995; 16: 586-90.
7. Judd LL, Kessler RC, Paulus MI, Zeller PV, Wittchen H-U, Kunovac JL. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand 1998; 98 (Suppl 393): 6-11. (Pubitemid 28428186)
8. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey. Arch Gen Psychiatry1994; 51: 355-64. (Pubitemid 24176813)
9. Roy-Byrne PP, Katon W. Generalized anxiety disorder in primary care: the precursor/modifier pathway to increased health care utilization. J Clin Psychiatry 1997; 58 Suppl 3: 34-8.
10. Wittchen HU, Kessler RC, Beesdo K, Krause P, Höfler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63 (Suppl 8): 24-34. (Pubitemid 34535254)
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM-III, American Psychiatic Association. Washington DC, 1980.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-III-R, American Psychiatric Association. Washington DC, 1987.
13. Angst, J, Gama A, Bienvenu OJ, et al. Varying temporal criteria for generalized anxiety disorder: prevalence and clinical characteristics in a young age cohort. Psychol Med 2006; 36: 1283-1292. (Pubitemid 44184704)
14. DSM5 Development. Available at http://www.dsm5.org/Pages/- Default.aspx
15. Lee S, Tsang A, Ruscio AM, et al. Implications of modifying the duration requirement of generalized anxiety disorder in developed and developing countries. Psychol Med 2009; 39: 1163-76.
16. Ruscio AM, Chiu WT, Roy-Byrne P, et al. Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication. J Anxiety Disord 2007; 21; 662-76. (Pubitemid 46817878)
17. Kessler RC, Brandenburg N, Lane M, et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med 2005; 35: 1073-82. (Pubitemid 41015705)
18. Katzman MA. Current Considerations in the Treatment of Generalized Anxiety Disorder. CNS Drugs 2009; 23: 103-20.
19. Lobo A, Chamorro L, Luque A, et al. Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales. Med Clin (Barc) 2002; 118: 493-9. (Pubitemid 34814804)
20. Guy W. ECDEU Assessment Manual for Psychopharmacology, U.S. Department of Health, Education, and Welfare: Rockville, MD, 1976.
21. Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med 2005; 6(1): 41-4.
22. Hays RD, Stewart AL. Sleep measures. In Measuring functioning and well-being: The Medical Outcomes Study approach ed. Eare, (A.L.S.J.E.) Durham, NC: Duke University Press 1992; pp. 235-259.
23. Luciano JV, Ayuso-Mateos JL, Fernández A, Serrano-Blanco A, Roca M, Haro JM. Psychometric properties of the twelve item World Health Organization Disability Assessment Schedule II (WHO-DAS II) in Spanish primary care patients with a first major depressive episode. J Affect Disord 2009; 121(1-2): 52-8.
24. Badia X, Roset M, Montserrat S, Herdman M, Segura A. The Spanish version of EuroQol: a description and its applications. European Quality of Life scale. Med Clin (Barc) 1999; 112 (Suppl 1): 79-85.
25. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27(3 Suppl): S178-89.
26. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53-72. (Pubitemid 26191458)
27. Carter RM, Wittchen HU, Pfister H, Kessler RC. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 2001; 13, 78-88. (Pubitemid 32240185)
28. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19: 567-96. (Pubitemid 41578819)
29. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008; 9: 248-312.
30. Durán A, Lara JL, van Waveren M. Spain: Health system review. Health Syst Trans 2006; 8: 1-208.
31. Lee S, Ma YL, Tsang A, Kwok K. Generalized anxiety disorder with and without excessive worry in Hong Kong. Depress Anxiety 2009.
32. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617-27. (Pubitemid 40973437)
33. König HH, Born A, Heider D, et al. Cost-effectiveness of a primary care model for anxiety disorders. Br J Psychiatry 2009; 195: 308-17 .
34. Perez C, Navarro A, Saldana MT, Martinez S, Rejas J. Patientreported outcomes in subjects with painful trigeminal neuralgia receiving pregabalin: evidence from medical practice in primary care settings. Cephalalgia 2009; 29: 781-90.